Few studies have evaluated long-term and progressive beneficial effects of omalizumab uninterrupted treatment for > 5 years in real-life practice.
The aim of this study was to evaluate the clinical and functional improvement of patients with persistent severe asthma treated with omalizumab for 5 years.
A retrospective, observational study based on medical record reviews of patients treated with omalizumab for minimum 5 years was addressed. Annual asthma exacerbations (AE), emergency visits (EV), hospital admissions (HA), systemic corticosteroid bursts (SCOb), inhaled corticosteroids daily dose (ICS/d) and lung function (FEV1% predicted) were collected during the pre-treatment year and compared after 1 and 5 years of uninterrupted therapy. Adverse reactions (AR) were also reviewed.
14 patients were evaluated. The average age was 41.64, nine patients were female and 13 had allergic asthma. Mean values before omalizumab treatment were total IgE 767.37 KU/L, FEV1 77%, ICS/d 1000 mcg (Fluticasone), SCOb 5.5, AE 7.14, EV 3.57 and HA 0.86. AER, ERV, SCOb reduced by 65%, 80%, 73%, respectively at year 1 and 92%, 96%, 83%, respectively at year 5 of treatment. Mean FEV1 increased up 87% at year 1 and up 105 % at year 5. Pre-treatment ICS/d dose reduced by 28 % at year five and only one patient suffered 1HA at year five. Only 2 patients experienced mild headache and no serious AR were documented.
Omalizumab showed an excellent tolerability and a progressive long-term effectiveness over 5 years in real-life practice, although the most improvements were experimented within the first year of treatment.